Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Investing Activities (2016 - 2026)

Corvus Pharmaceuticals' Cash from Investing Activities history spans 12 years, with the latest figure at -$144.8 million for Q1 2026.

  • Quarterly Cash from Investing Activities fell 3513.76% to -$144.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$156.9 million through Mar 2026, down 575.24% year-over-year, with the annual reading at -$7.8 million for FY2025, 71.63% up from the prior year.
  • Cash from Investing Activities came in at -$144.8 million for Q1 2026, down from $10.9 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $17.5 million in Q3 2023 to a low of -$144.8 million in Q1 2026.
  • The 5-year median for Cash from Investing Activities is -$2.6 million (2025), against an average of -$11.1 million.
  • Year-over-year, Cash from Investing Activities skyrocketed 60714.29% in 2025 and then crashed 3513.76% in 2026.
  • Corvus Pharmaceuticals' Cash from Investing Activities stood at -$3.9 million in 2022, then surged by 40.29% to -$2.3 million in 2023, then plummeted by 162.42% to -$6.1 million in 2024, then soared by 278.86% to $10.9 million in 2025, then plummeted by 1431.31% to -$144.8 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Cash from Investing Activities are -$144.8 million (Q1 2026), $10.9 million (Q4 2025), and -$2.6 million (Q3 2025).